View Financial HealthGenvor 배당 및 자사주 매입배당 기준 점검 0/6Genvor 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-7.2%자사주 매입 수익률총 주주 수익률-7.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 23Genvor Incorporated Appoints Donald Kalkofen as Chief Financial OfficerGenvor Incorporated announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health and wellness. Mr. Kalkofen brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions. Most recently, he served as Chief Financial Officer of Alpha Cognition Inc., a publicly traded CNS-focused biotechnology company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s, where he led the preparations for the company’s successful NASDAQ listing and helped to establish new banking, audit committee, and investor relations functions. Prior to Alpha Cognition, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics, a publicly traded clinical-stage biopharmaceutical company, where he helped guide the company’s strong growth and supported the company’s successful SOX 404(b) implementation. Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, where he took the bank public on NASDAQ and led growth from $90 million to $1.5 billion in assets. Mr. Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University.공시 • Feb 11Genvor, Inc. Announces the Publication of Peer-Reviewed Research Validated Its Proprietary Agm182 Antifungal Peptide Technology in PhytofrontiersGenvor Inc. announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™?, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture's Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination. Aflatoxins are naturally occurring toxic and carcinogenic compounds produced by Aspergillus flavus that contain corn and other crops, posing significant risks to human and animal health. Economic losses fromungal diseases in corn are substantial, with total annual U.S. losses estimated between $3 billion and $5 billion. Aflatoxin contamination alone has potential annual market impacts ranging from approximately $52 million in lower-risk years to $1.68 billion in high-risk years. The peer-reviewed publication follows Genvor's November 2025 announcement that the USPTO issued U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both intellectual property protection and independent scientific validation of the technology's commercial potential. The research was conducted at the USDA-ARS Food and Feed Safety Research Unit at the Southern Regional Research Center in New Orleans, Louisiana, in collaboration with scientists from Tuskegee University and Genvor. The study builds on Genvor's over 7-year Cooperative Research and Development Agreement (CRADA) with the USDA-ARS, which focuses on developing corn varieties resistant to pre-harvest aflatoxin contamination.공시 • Jan 28Genvor, Inc. Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, Effective February 2, 2026Genvor Inc. announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. In this role, Dr. Stavrides will lead Genvor’s commercial strategy and execution, focusing on expanding strategic partnerships, licensing agreements, and collaboration opportunities with global agricultural companies. Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally (microbials, extracts, pheromones), quadrupling revenues over a seven-year period. Previously, Dr. Stavrides held various global regulatory, strategy and marketing positions, in both agrochemicals and biocontrols. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years. Dr. Stavrides is a biochemist and also holds a Ph.D. in Genomics from Cambridge University (Human Genome Project) and an MBA from INSEAD.공시 • Dec 12Genvor Incorporated Auditor Raises 'Going Concern' DoubtGenvor Incorporated filed its 10-K on Dec 10, 2025 for the period ending Sep 30, 2025. In this report its auditor, Novogradac & Company LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.공시 • Dec 06Genvor Incorporated announced that it expects to receive $7 million in fundingGenvor Incorporated announced that it will receive $70,00,000 in funding on December 5, 2025. The company will issue common shares and warrants in the transaction. The minimum investment accepted from any outside investor is $10,000. The company will issue securities pursuant to exemption provided under Regulation D.공시 • Aug 14Genvor Incorporated announced delayed 10-Q filingOn 08/13/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 13Genvor Incorporated announced delayed 10-Q filingOn 05/12/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Feb 19Genvor Incorporated announced delayed 10-Q filingOn 02/18/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Feb 01Genvor Incorporated announced delayed annual 10-K filingOn 01/31/2025, Genvor Incorporated announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Oct 23Genvor Incorporated Announces the Resignation of Judith S. Miller as Member of the Board of DirectorsOn August 7, 2024, Judith S. Miller resigned as a member of the Board of Directors of Genvor Incorporated (the Company).공시 • Aug 16Genvor Incorporated announced delayed 10-Q filingOn 08/15/2024, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jan 18Genvor Incorporated Appoints Judith Miller as Chief Business OfficerGenvor Incorporated announced Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer.공시 • Jan 17Genvor Incorporated Announces CEO ChangesGenvor Incorporated announced Chad Pawlak, Sr., global Agribusiness executive, has been appointed as Chief Executive Officer of Genvor, effective immediately. Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer. Chad Pawlak, Sr. brings over 30 years of experience with a proven track record of driving revenue growth and fostering strategic partnerships across agribusiness, regenerative agriculture, carbon marketing, food, and sustainability - particularly in soil and water conservation. He has a deep understanding of regenerative agriculture, biotechnology, crop cultivation, livestock management, dairy production, and consumer packaged goods (CPG). Most recently he was Chief Executive Officer of Locus Agricultural Solutions, an agricultural biological company, where he led the strategic growth plan through cross-functional collaboration, resulting in over 350,000 acres of enrollment in a nature-based carbon credit project utilizing a biological product as the practice change. Chad has previous experience as the U.S.-Canada Crop & Plant Protection Business Director Lead - Botanicals for MGK (a part of Valent USA & Sumitomo Chemical). In this role, he was responsible for the overall design of the strategic business plan of the $30 million Botanical & Organic Crop Protection segments in the U.S. & Canada. He holds an MBA from the Jack Welch Management Institute and BS & AOS in Marketing and Advertising/Public Relations from Johnson & Wales University.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 GNVR 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: GNVR 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Genvor 배당 수익률 vs 시장GNVR의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (GNVR)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (GNVR) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 GNVR 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 GNVR 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 GNVR 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: GNVR 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 01:49종가2026/05/19 00:00수익2026/03/31연간 수익2025/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Genvor Incorporated는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 23Genvor Incorporated Appoints Donald Kalkofen as Chief Financial OfficerGenvor Incorporated announced the appointment of Donald Kalkofen as Chief Financial Officer. In this role, Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health and wellness. Mr. Kalkofen brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions. Most recently, he served as Chief Financial Officer of Alpha Cognition Inc., a publicly traded CNS-focused biotechnology company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s, where he led the preparations for the company’s successful NASDAQ listing and helped to establish new banking, audit committee, and investor relations functions. Prior to Alpha Cognition, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics, a publicly traded clinical-stage biopharmaceutical company, where he helped guide the company’s strong growth and supported the company’s successful SOX 404(b) implementation. Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, where he took the bank public on NASDAQ and led growth from $90 million to $1.5 billion in assets. Mr. Kalkofen is a Certified Public Accountant (inactive) and holds a Bachelor of Arts in Accounting from Washington State University.
공시 • Feb 11Genvor, Inc. Announces the Publication of Peer-Reviewed Research Validated Its Proprietary Agm182 Antifungal Peptide Technology in PhytofrontiersGenvor Inc. announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™?, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture's Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination. Aflatoxins are naturally occurring toxic and carcinogenic compounds produced by Aspergillus flavus that contain corn and other crops, posing significant risks to human and animal health. Economic losses fromungal diseases in corn are substantial, with total annual U.S. losses estimated between $3 billion and $5 billion. Aflatoxin contamination alone has potential annual market impacts ranging from approximately $52 million in lower-risk years to $1.68 billion in high-risk years. The peer-reviewed publication follows Genvor's November 2025 announcement that the USPTO issued U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both intellectual property protection and independent scientific validation of the technology's commercial potential. The research was conducted at the USDA-ARS Food and Feed Safety Research Unit at the Southern Regional Research Center in New Orleans, Louisiana, in collaboration with scientists from Tuskegee University and Genvor. The study builds on Genvor's over 7-year Cooperative Research and Development Agreement (CRADA) with the USDA-ARS, which focuses on developing corn varieties resistant to pre-harvest aflatoxin contamination.
공시 • Jan 28Genvor, Inc. Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, Effective February 2, 2026Genvor Inc. announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. In this role, Dr. Stavrides will lead Genvor’s commercial strategy and execution, focusing on expanding strategic partnerships, licensing agreements, and collaboration opportunities with global agricultural companies. Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally (microbials, extracts, pheromones), quadrupling revenues over a seven-year period. Previously, Dr. Stavrides held various global regulatory, strategy and marketing positions, in both agrochemicals and biocontrols. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years. Dr. Stavrides is a biochemist and also holds a Ph.D. in Genomics from Cambridge University (Human Genome Project) and an MBA from INSEAD.
공시 • Dec 12Genvor Incorporated Auditor Raises 'Going Concern' DoubtGenvor Incorporated filed its 10-K on Dec 10, 2025 for the period ending Sep 30, 2025. In this report its auditor, Novogradac & Company LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
공시 • Dec 06Genvor Incorporated announced that it expects to receive $7 million in fundingGenvor Incorporated announced that it will receive $70,00,000 in funding on December 5, 2025. The company will issue common shares and warrants in the transaction. The minimum investment accepted from any outside investor is $10,000. The company will issue securities pursuant to exemption provided under Regulation D.
공시 • Aug 14Genvor Incorporated announced delayed 10-Q filingOn 08/13/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 13Genvor Incorporated announced delayed 10-Q filingOn 05/12/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Feb 19Genvor Incorporated announced delayed 10-Q filingOn 02/18/2025, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Feb 01Genvor Incorporated announced delayed annual 10-K filingOn 01/31/2025, Genvor Incorporated announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Oct 23Genvor Incorporated Announces the Resignation of Judith S. Miller as Member of the Board of DirectorsOn August 7, 2024, Judith S. Miller resigned as a member of the Board of Directors of Genvor Incorporated (the Company).
공시 • Aug 16Genvor Incorporated announced delayed 10-Q filingOn 08/15/2024, Genvor Incorporated announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jan 18Genvor Incorporated Appoints Judith Miller as Chief Business OfficerGenvor Incorporated announced Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer.
공시 • Jan 17Genvor Incorporated Announces CEO ChangesGenvor Incorporated announced Chad Pawlak, Sr., global Agribusiness executive, has been appointed as Chief Executive Officer of Genvor, effective immediately. Judith Miller has been asked to remain and transition from her successful Interim Chief Executive Officer position to serve as Chief Business Officer. Chad Pawlak, Sr. brings over 30 years of experience with a proven track record of driving revenue growth and fostering strategic partnerships across agribusiness, regenerative agriculture, carbon marketing, food, and sustainability - particularly in soil and water conservation. He has a deep understanding of regenerative agriculture, biotechnology, crop cultivation, livestock management, dairy production, and consumer packaged goods (CPG). Most recently he was Chief Executive Officer of Locus Agricultural Solutions, an agricultural biological company, where he led the strategic growth plan through cross-functional collaboration, resulting in over 350,000 acres of enrollment in a nature-based carbon credit project utilizing a biological product as the practice change. Chad has previous experience as the U.S.-Canada Crop & Plant Protection Business Director Lead - Botanicals for MGK (a part of Valent USA & Sumitomo Chemical). In this role, he was responsible for the overall design of the strategic business plan of the $30 million Botanical & Organic Crop Protection segments in the U.S. & Canada. He holds an MBA from the Jack Welch Management Institute and BS & AOS in Marketing and Advertising/Public Relations from Johnson & Wales University.